RET and non-small cell lung carcinoma: At the data cutoff, 281 RET + NSCLC (116 treatment naïve and 141 previously pretreated) (efficacy population) were enrolled, of whom 260 (107 and 130, respectively) had measurable disease (measurable disease population).